DIA: Driving Insights to Action
Science:Life Sciences
Risk-based monitoring (RBM) was codified into clinical research by the November 2016 Integrated Addendum to the ICH GCP Guideline (E6[R2]). Many organizations now face challenges in implementing RBM in an R&D environment which is simultaneously (and increasingly) impacted by machine learning and artificial intelligence. “Process automation has advanced to make large numbers of tasks ‘invisible,’ ‘behind the scenes’ in the computer and that leaves only the tasks that matter most available for us as humans to execute,” explains Gregg Larson, Vice President of Clinical Operations at Ultragenyx Pharmaceutical, Inc. “Technology has not yet evolved to the point of thinking for humans. We still have to do the thinking.”
GPP Experts Explain Authorship Algorithm
"Dossier in the Cloud" Democratizing Global Access
DIA: A Place Where You Can Make a Difference
Autumn’s Leukemia Story: Regimens, Recovery, and Realizations
Retiring TGA Head Maps Australia’s Post-Pandemic Future
Patient Engagement: Evolution of Who Knows What, Part 2
Patient Engagement: Evolution of Who Knows What, Part 1
Australian Clinical Trials Alliance Part 2 – Future Projections
ANVISA Explains Innovative Online Optimized Assessment Project
Australian Clinical Trials Alliance Part 1 – Current Perceptions
Looking Back and Ahead: Translational Science Advances Impacting Patient Care
Rwanda Welcomes African Medicines Agency Home
Will Technology Solve the Research “People Problem”?
Why Trans/Nonbinary Research Benefits All Communities
Digital Revolutionizing Data-Driven Reimbursement
China Sets New Record for Local Drug Approvals in 2021
WHO Pilot Formalizes CSA Process to Assist Developers
Medication Errors Emerge as Global Patient Safety Issue
What We Are Missing by Not Including ”Who?”
Cancer Data Ecosystem Powering Moonshot Relaunch
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Speaking of Psychology
Stuff To Blow Your Mind